San Diego-based Conatus Pharmaceuticals said Friday afternoon that it has closed a $20M, Series B funding round. The firm, which is developing treatments for Hepatitis C, said the funding was led by AgeChem Venture Fund, and also included Aberdare Ventures, Advent Venture Partners, Bay City Capital, Gilde Healthcare Partners, and Roche Venture Fund. The firm said the funding would go towards clinical development of its CTS-1027 drug candidate. Louis Lacasse of AgeChem joins the firm's board as part of the funding. More information »